FDA Authorizes Updated Novavax COVID-19 Vaccine
The FDA amended the emergency use authorization of the Novavax COVID-19 vaccine, adjuvanted to include the 2023-2024 formula.
The FDA amended the emergency use authorization of the Novavax COVID-19 vaccine, adjuvanted to include the 2023-2024 formula.
Health Canada has granted authorization for Novavax Inc's COVID-19 vaccine "Nuvaxovid" for adults age 18 and older.
Novavax has completed its rolling regulatory submission for authorization of its NVX-CoV2373 COVID-19 vaccine candidate in the United Kingdom.